{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:06:47Z","timestamp":1789988807230,"version":"4.0.1"},"reference-count":61,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Tumors of the spine and spinal cord, including primary and metastatic vertebral tumors, intramedullary gliomas, and refractory intradural lesions, are challenging to treat because curative local therapy is limited by the eloquent, nonregenerating neural tissue surrounding them. Oncolytic virotherapy may offer a rational alternative by combining tumor-selective oncolysis with the induction of systemic antitumor immunity, while sparing normal neural cells. This review summarizes the current field of oncolytic viruses, including adenovirus, herpes simplex virus, reovirus, and others, in the context of spinal and spinal cord tumors. Clinical data in the spine remain scarce; however, the rationale is based on histological evidence from sarcomas and other tumors, extensive glioma experience, including diffuse intrinsic pontine glioma, and preclinical activity in nerve sheath and meningioma models. We discuss the telomerase-specific oncolytic adenovirus OBP-301 and its derivatives, whose hTERT-driven replication provides histology-agnostic tumor selectivity, while sparing the telomerase-silent spinal cord. This telomerase dependence, however, limits activity against tumors that maintain telomeres through the alternative lengthening of telomeres (ALT) pathway, such as many osteosarcomas and some spinal cord astrocytomas. We also discuss delivery and safety within the confined spinal canal, combination strategies, and future directions, such as extracellular vesicle-mediated delivery and biomarker-guided patient selection. Although clinical translation to the spine will require dedicated preclinical and early-phase studies, virotherapy represents a promising, mechanistically grounded modality for these therapeutically challenging tumors.<\/jats:p>","DOI":"10.3390\/microorganisms14092110","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:25:43Z","timestamp":1789986343000},"page":"2110","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Virotherapy for Spinal and Spinal Cord Tumors: Current Evidence and Future Perspectives"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5594-1292","authenticated-orcid":false,"given":"Koji","family":"Uotani","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4257-9180","authenticated-orcid":false,"given":"Tomohiro","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Takatori","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenzaburo","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Oda","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Shinohara","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4658-1050","authenticated-orcid":false,"given":"Hiroshi","family":"Tazawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5377-6051","authenticated-orcid":false,"given":"Toshiyoshi","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1732-9307","authenticated-orcid":false,"given":"Toshifumi","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/nop\/npaa049","article-title":"An overview of the tumors affecting the spine\u2014Inside to out","volume":"7","author":"Kumar","year":"2020","journal-title":"Neuro-Oncol. Pract."},{"key":"ref_2","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Morimoto, T., Toda, Y., Hakozaki, M., Paholpak, P., Watanabe, K., Kato, K., Tsukamoto, M., Hirata, H., Kaneuchi, Y., and Tome, Y. (2024). A new era in the management of spinal metastasis. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1374915"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jocn.2019.02.001","article-title":"A systematic review of outcome in intramedullary ependymoma and astrocytoma","volume":"63","author":"Hamilton","year":"2019","journal-title":"J. Clin. Neurosci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/sj.sc.3102130","article-title":"Surgical treatment of intramedullary spinal cord tumors: Prognosis and complications","volume":"46","author":"Nakamura","year":"2008","journal-title":"Spinal Cord"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Ariyaratne, S., Jenko, N., Iyengar, K.P., James, S., Mehta, J., and Botchu, R. (2023). Primary osseous malignancies of the spine. Diagnostics, 13.","DOI":"10.3390\/diagnostics13101801"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.canlet.2007.02.002","article-title":"Oncolytic viruses in cancer therapy","volume":"254","author":"Hinkkanen","year":"2007","journal-title":"Cancer Lett."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1476-4598-12-103","article-title":"Oncolytic viruses as therapeutic cancer vaccines","volume":"12","author":"Bartlett","year":"2013","journal-title":"Mol. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Guo, Z.S., Liu, Z., and Bartlett, D.L. (2014). Oncolytic immunotherapy: Dying the right way is a key to eliciting potent antitumor immunity. Front. Oncol., 4.","DOI":"10.3389\/fonc.2014.00074"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: A phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","article-title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: A phase 1\/2 trial","volume":"29","author":"Nassiri","year":"2023","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/mt.2009.266","article-title":"Current issues and future directions of oncolytic adenoviruses","volume":"18","author":"Yamamoto","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1158\/1078-0432.CCR-1075-3","article-title":"Telomerase-specific replication-selective virotherapy for human cancer","volume":"10","author":"Kawashima","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/mt.2009.262","article-title":"A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors","volume":"18","author":"Nemunaitis","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/sj.cgt.7700944","article-title":"Oncolysis and suppression of tumor growth by a GFP-expressing oncolytic adenovirus controlled by an hTERT and CMV hybrid promoter","volume":"13","author":"Davis","year":"2006","journal-title":"Cancer Gene Ther."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Uotani, K., Tazawa, H., Hasei, J., Fujiwara, T., Yoshida, A., Yamakawa, Y., Omori, T., Sugiu, K., Komatsubara, T., and Kondo, H. (2024). Fluorescence-guided assessment of bone and soft-tissue sarcomas for predicting the efficacy of telomerase-specific oncolytic adenovirus. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0298292"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"200822","DOI":"10.1016\/j.omton.2024.200822","article-title":"Translation of oncolytic viruses in sarcoma","volume":"32","author":"Robinson","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Karadimas, T., Huynh, T.H., Chose, C., Zervoudakis, G., Clampitt, B., Lapp, S., Joyce, D., Letson, G.D., Metts, J., and Binitie, O. (2024). Oncolytic viral therapy in osteosarcoma. Viruses, 16.","DOI":"10.3390\/v16071139"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Tazawa, H., Hasei, J., Yano, S., Kagawa, S., Ozaki, T., and Fujiwara, T. (2020). Bone and soft-tissue sarcoma: A new target for telomerase-specific oncolytic virotherapy. Cancers, 12.","DOI":"10.3390\/cancers12020478"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/00003086-198011000-00013","article-title":"A system for the surgical staging of musculoskeletal sarcoma","volume":"153","author":"Enneking","year":"1980","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/00007632-199705010-00020","article-title":"Primary bone tumors of the spine: Terminology and surgical staging","volume":"22","author":"Boriani","year":"1997","journal-title":"Spine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9078","DOI":"10.1038\/s41598-020-65326-0","article-title":"Sagittal en bloc resection of primary tumors in the thoracic and lumbar spine: Feasibility, safety and outcome","volume":"10","author":"Dang","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3171\/2012.11.SPINE12111","article-title":"Local disease control for spinal metastases following \u201cseparation surgery\u201d and adjuvant hypofractionated or high-dose single-fraction stereotactic radiosurgery","volume":"18","author":"Laufer","year":"2013","journal-title":"J. Neurosurg. Spine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1634\/theoncologist.2012-0293","article-title":"The NOMS framework: Approach to the treatment of spinal metastatic tumors","volume":"18","author":"Laufer","year":"2013","journal-title":"Oncologist"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"E1221","DOI":"10.1097\/BRS.0b013e3181e16ae2","article-title":"A novel classification system for spinal instability in neoplastic disease","volume":"35","author":"Fisher","year":"2010","journal-title":"Spine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1148\/rg.2019180200","article-title":"Intradural extramedullary spinal neoplasms: Radiologic-pathologic correlation","volume":"39","author":"Koeller","year":"2019","journal-title":"Radiographics"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/neuonc\/noy104","article-title":"TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma","volume":"20","author":"Neumayer","year":"2018","journal-title":"Neuro-Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/bpa.12110","article-title":"High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression","volume":"24","author":"Goutagny","year":"2014","journal-title":"Brain Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1089\/thy.2005.15.977","article-title":"Variable expression of coxsackie-adenovirus receptor in thyroid tumors: Implications for adenoviral gene therapy","volume":"15","author":"Marsee","year":"2005","journal-title":"Thyroid"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Schwertner, B., Lindner, G., Toledo Stauner, C.T., Klapproth, E., Magnus, C., Rohrhofer, A., Gross, S., Schuler-Thurner, B., \u00d6ttl, V., and Feichtgruber, N. (2021). Nectin-1 expression correlates with the susceptibility of malignant melanoma to oncolytic herpes simplex virus in vitro and in vivo. Cancers, 13.","DOI":"10.3390\/cancers13123058"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/sj.cgt.7700947","article-title":"Expression of the coxsackievirus- and adenovirus receptor in gastrointestinal cancer correlates with tumor differentiation","volume":"13","author":"Korn","year":"2006","journal-title":"Cancer Gene Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/gt.2014.72","article-title":"Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines","volume":"21","author":"Jackson","year":"2014","journal-title":"Gene Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1158\/1078-0432.217.11.1","article-title":"A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas","volume":"11","author":"Henson","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.ajpath.2011.06.018","article-title":"Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes","volume":"179","author":"Heaphy","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1002\/ijc.27589","article-title":"Genetically engineered oncolytic adenovirus induces autophagic cell death through an E2f1-microRNA-7-epidermal growth factor receptor axis","volume":"131","author":"Tazawa","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Tazawa, H., Kuroda, S., Hasei, J., Kagawa, S., and Fujiwara, T. (2017). Impact of autophagy in oncolytic adenoviral therapy for cancer. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18071479"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"eaam7577","DOI":"10.1126\/scitranslmed.aam7577","article-title":"Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade","volume":"10","author":"Samson","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1016\/j.ymthe.2017.08.016","article-title":"Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I\/IIa glioblastoma trial","volume":"25","author":"Geletneky","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41467-023-43076-7","article-title":"Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: A phase 1 trial","volume":"15","author":"Galanis","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1158\/1078-0432.CCR-10-2066","article-title":"Preclinical evaluation of telomerase-specific oncolytic virotherapy for human bone and soft tissue sarcomas","volume":"17","author":"Sasaki","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41417-023-00720-0","article-title":"BETA prime: A first-in-man phase 1 study of ADAPT-001, an armed oncolytic adenovirus for solid tumors","volume":"31","author":"Conley","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"978","DOI":"10.14245\/ns.2244290.145","article-title":"Spinal metastases and the evolving role of molecular targeted therapy, chemotherapy, and immunotherapy","volume":"19","author":"Fomchenko","year":"2022","journal-title":"Neurospine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/gt.2014.110","article-title":"The systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer","volume":"22","author":"Xu","year":"2015","journal-title":"Gene Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1056\/NEJMoa2202028","article-title":"Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma","volume":"386","author":"Labiano","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/neuonc\/not317","article-title":"Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus","volume":"16","author":"Antoszczyk","year":"2014","journal-title":"Neuro-Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1517\/21678707.2016.1128322","article-title":"Prospects and progress of oncolytic viruses for treating peripheral nerve sheath tumors","volume":"4","author":"Antoszczyk","year":"2016","journal-title":"Expert Opin. Orphan Drugs"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"113843","DOI":"10.1016\/j.biopha.2022.113843","article-title":"Histone deacetylase inhibitors enhance oncolytic herpes simplex virus therapy for malignant meningioma","volume":"155","author":"Kawamura","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"11417","DOI":"10.1038\/s41598-018-29736-5","article-title":"Magnetic drug targeting: A novel treatment for intramedullary spinal cord tumors","volume":"8","author":"Kheirkhah","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"van der Meulen-Muileman, I.H., Amado-Azevedo, J., Lamfers, M.L.M., Kleijn, A., Idema, S., Noske, D.P., Dirven, C.M.F., and van Beusechem, V.W. (2025). Adenovirus-neutralizing and infection-promoting activities measured in serum of human brain cancer patients treated with oncolytic adenovirus Ad5-\u220624.RGD. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26020854"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"21560","DOI":"10.1038\/s41598-022-26030-3","article-title":"Effects of pre-existing anti-adenovirus antibodies on transgene expression levels and therapeutic efficacies of arming oncolytic adenovirus","volume":"12","author":"Ono","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1200\/JCO.2023.41.16_suppl.4052","article-title":"Phase II study of telomelysin (OBP-301) in combination with pembrolizumab in gastroesophageal adenocarcinoma","volume":"41","author":"Ku","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejca.2021.04.043","article-title":"Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (Telomelysin) with radiotherapy in oesophageal cancer patients unfit for standard treatments","volume":"153","author":"Shirakawa","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.2174\/138920112800958887","article-title":"Synergistic interaction of telomerase-specific oncolytic virotherapy and chemotherapeutic agents for human cancer","volume":"13","author":"Fujiwara","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Ponterio, E., Haas, T.L., and De Maria, R. (2024). Oncolytic virus and CAR-T cell therapy in solid tumors. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1455163"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Garofalo, M., Villa, A., Rizzi, N., Kuryk, L., Mazzaferro, V., and Ciana, P. (2018). Systemic administration and targeted delivery of immunogenic oncolytic adenovirus encapsulated in extracellular vesicles for cancer therapies. Viruses, 10.","DOI":"10.3390\/v10100558"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jconrel.2018.05.015","article-title":"Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment","volume":"283","author":"Garofalo","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Wu, J., Zhang, H., Wei, J., and Wu, J. (2020). Extracellular vesicles-mimetic encapsulation improves oncolytic viro-immunotherapy in tumors with low coxsackie and adenovirus receptor. Front. Bioeng. Biotechnol., 8.","DOI":"10.3389\/fbioe.2020.574007"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Khilar, S., Dembinska-Kenner, A., Hall, H., Syrmos, N., Ligarotti, G.K.I., Plaha, P., Apostolopoulos, V., Chibbaro, S., Barbagallo, G.M.V., and Ganau, M. (2025). Towards a new dawn for neuro-oncology: Nanomedicine at the service of drug delivery for primary and secondary brain tumours. Brain Sci., 15.","DOI":"10.3390\/brainsci15020136"}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/14\/9\/2110\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:50:42Z","timestamp":1789987842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/14\/9\/2110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":61,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["microorganisms14092110"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms14092110","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]}}}